Triptorelin Market To Touch US$ 670 Million By 2027 At A 5.2% CAGR | Generated Opportunities For Growth In The Global Triptorelin Industry

Among the numerous medications for achieving medical castration, gonadotropin-releasing hormone (GnRH) agonists have a better safety and effectiveness profile than estrogens and anti-androgens. Furthermore, slow-release GnRH agonist formulations provide patients with more flexibility, better quality of life, and ultimately save costs.

Prostate cancer usually advances as the level of testosterone in the body rises. Furthermore, testosterone production can be halted through surgical removal of the testicles or long-term pharmaceutical therapy. Triptorelin is a GnRH agonist that works by preventing the tentacles from producing testosterone. This decreases testosterone levels over time, slowing the spread of prostate cancer.

Request Here Sample Report

The prominent players in the Triptorelin Market are Ipsen, Bachem, Ferring Pharmaceuticals Pvt Ltd., Chengdu Tiantaishan pharmaceutical Co., Ltd., Tecnofarma, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.), Debiopharm Group, and Arbor Pharmaceuticals, LLC.

Luteinising Hormone-Releasing Hormone analogue triptorelin is a decapeptide analogue (LHRH, also called gonadotropin-releasing hormone [GnRH]). Triptorelin is widely used in the palliative treatment of advanced prostate cancer that is hormone dependent.

Moreover, according to National Institute for Health and Care Excellence (NICE), in May 2013, the licensed indications for luteinising hormone-releasing hormone (LHRH) agonist: triptorelin were extended to include two new indications for prostate cancer: first in neoadjuvant treatment before radiotherapy in high-risk localized or locally advanced disease and second in adjuvant treatment to radical prostatectomy in locally advanced disease at high risk of progression. Triptorelin is administrated intramuscularly or subcutaneously.

Additionally, triptorelin is prescribed for the treatment of Central Precocious Puberty in children aged two and up (CPP). In July 2017, U.S. Food and Drug Administration (FDA), approved Arbor Pharmaceuticals’: Triptodur, in pediatric patients with central precocious puberty. The approval comes after a phase 3 clinical trial (Efficacy, Safety, and Pharmacokinetics [PK] of Triptorelin 6-month Formulation in Patients with Central Precocious Puberty), which looked at the effects of triporelin medication on prepubertal luteinizing hormone levels. Study demonstrated a return to pre-pubertal luteinizing hormone (LH) levels in 93% of enrolled patients, with pre-pubertal luteinizing hormone (LH) suppression maintained at 12 months by 98% of patients.

Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/1963

Triptorelin, a GnRH agonist, is a first-line hormonal treatment that has shown efficacy and safety in individuals with non-metastatic or metastatic prostate cancer in clinical trials. Triptorelin is also being explored for a variety of therapy alternatives, which is still in the early stages of clinical trials. For example, GnRH analogue, triptorelin is being studied to analyze their efficacy and safety for HIV-1 reservoir reduction in Antiretroviral Therapy (ART) treated HIV-1 infected patients. According to ClinicalTrials.gov, in May 2018, this study was conducted by Immune System Regulation AB, and currently in phase II clinical stage.

Triptorelin is also being studied to see how Tamoxifen, Letrozole, and Letrozole + Zoledronate affect bone loss in breast cancer patients who are on adjuvant hormone therapy. According to ClinicalTrials.gov, this study was initiated in July 2017 by the National Cancer Institute (NCI), Naples, and is now in phase III clinical trials.  Furthermore, with the successful conclusion of this study and the probable launch of new products during the forecast period, the triptorelin market exhibits attractive revenue development in the near future.

Furthermore, triptorelin’s increased efficacy and effectiveness in suppressing gonadotropin in Central Precocious Puberty (CPP) among young boys and girls is projected to propel the triptorelin market growth. For example, according to data published in the Scientific World Journal, in May 2012, triptorelin 11.25 mg per 90 days efficiently suppressed the pituitary-gonadal level in children with CPP from first administration.

In addition, considerable research and development is being done on the use of androgen deprivation therapy with triptorelin to slow the course of salivary gland cancers that express androgen receptors. For example, in January 2016, Debiopharm International SA collaborated with European Organization for Research and Treatment of Cancer (EORTC) to investigate Triptorelin for treatment of salivary gland cancer. Debiopharm International SA will provide a one-month formulation of triptorelin pamoate 3.75 mg to patients with salivary gland cancer who are enrolled in an EORTC-sponsored clinical trial.  Researchers will compare the efficacy and safety of androgen chemotherapy with androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor-expressing salivary gland malignancies during the clinical trial.

Request Here For PDF Brochure

The rising prevalence of prostate cancer worldwide, as well as the widespread use of triptorelin in prostate cancer treatment to slow the progression of the disease by lowering the amount of testosterone synthesised by the body, are expected to propel the triptorelin market forward during the forecast period.

For example, according to the World Cancer Research Fund (WCRF) International, 2012, over 1.1 million cases of prostate cancer were recorded, accounting for around 8% of all new cancer cases worldwide. Furthermore, the developed economies accounted for roughly 68 percent of prostate cancer incidences. The highest rates of prostate cancer were seen in Oceania and North America, with the lowest rates found in Asia and Africa.

Furthermore, according to Cancer Research UK, roughly 47,151 new cases of prostate cancer were documented in the United Kingdom in 2015. Furthermore, in 2015, prostate cancer accounted for 13% of all cancer cases in the United Kingdom. Prostate cancer was the second-leading cause of cancer deaths among men in the United Kingdom in 2014, accounting for 13% of all male cancer fatalities. In addition, according to the same source, 11,287 guys in the United Kingdom died of prostate cancer in 2014. According to the crude mortality rate, 36 men died of prostate cancer for every 100,000 men in the country.

Key players operating in triptorelin market include Ipsen, Bachem, Ferring Pharmaceuticals Pvt Ltd., Chengdu Tiantaishan pharmaceutical Co., Ltd., Tecnofarma, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.), Debiopharm Group, and Arbor Pharmaceuticals, LLC.

View Press Release For More Information

Related Reports:

Scopolamine Market, by Dosage Form (Tablet, Syrup, Injection, Patch, and Others), by Distribution Channel (Hospital Pharmacies, Retail pharmacies, and Online Pharmacies) – Global Forecast to 2027

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837